Malaysian Biotech Licenses Technology For Non-Cancer Therapy (Malaysia)
This article was originally published in PharmAsia News
Executive Summary
Malaysia's Biotechnology Corp. says it has made its first technology licensing agreement, with the French start-up Nanobiotix. The cost of the deal was not disclosed. Nanobiotix makes nanotechnology applications for cancer therapy. Biotech intends to license the nanotechnology for purposes other than cancer, the firm's current primary focus. Nanobiotix CEO Laurent Levy said the agreement would allow it to expand its pipeline into non-cancer areas. (Click here for more